首页> 外文期刊>Case Reports in Hematology >Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia
【24h】

Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia

机译:重组血栓调节蛋白在三氧化二砷治疗复发的急性早幼粒细胞白血病患者中成功控制弥散性血管内凝血

获取原文
           

摘要

Disseminated intravascular coagulation (DIC) frequently occurs in patients with acute promyelocytic leukemia (APL). With the induction of therapy in APL using all-trans retinoic acid (ATRA), DIC can be controlled in most cases as ATRA usually shows immediate improvement of the APL. However, arsenic trioxide (ATO) which has been used for the treatment of relapse in APL patients has shown to take time to suppress APL cells, therefore the control of DIC in APL with ATO treatment is a major problem. Recently, the recombinant soluble thrombomodulin fragment has received a lot of attention as the novel drug for the treatment of DIC with high efficacy. Here, we present a relapsed patient with APL in whom DIC was successfully and safely controlled by rTM during treatment with ATO.
机译:急性早幼粒细胞白血病(APL)患者经常发生弥散性血管内凝血(DIC)。通过使用全反式视黄酸(ATRA)在APL中诱导治疗,在大多数情况下DIC可以得到控制,因为ATRA通常显示出APL的即时改善。然而,已经被用于治疗APL患者复发的三氧化二砷(ATO)需要花费时间来抑制APL细胞,因此用ATO治疗控制APL中的DIC是一个主要问题。近年来,重组可溶性血栓调节蛋白片段作为治疗DIC的高效新药备受关注。在这里,我们介绍了一位复发的APL患者,其中在ATO治疗期间通过rTM成功且安全地控制了DIC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号